Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Type:
Grant
Filed:
August 4, 2022
Date of Patent:
December 20, 2022
Assignee:
Etubics Corporation
Inventors:
Joseph P. Balint, Frank R. Jones, Richard B. Gayle, III
Abstract: The present invention encompasses pet food compositions that include one or more probiotic microorganisms, which are useful to improve the health of companion animals. For example, the invention encompasses pet food compositions including a probiotic, for example, Lactobacillus, Bifidobacterium and Streptococcus (Enterococcus). The present invention also encompasses the preparation of pet food compositions including one or more probiotic microorganisms intended for methods of maintaining or improving pet health through feeding a pet a pet food composition including the probiotic microorganism.
Type:
Grant
Filed:
October 21, 2020
Date of Patent:
November 29, 2022
Assignee:
Hill's Pet Nutrition, Inc.
Inventors:
Pavinee Chinachoti, Kathy Gross, Christina Khoo, Luis Montelongo
Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.
Type:
Grant
Filed:
January 28, 2019
Date of Patent:
November 22, 2022
Assignee:
The Regents of the University of California
Inventors:
James D. Marks, Maria Consuelo Garcia Rodriguez, Jianbo Dong, Zhengda Sun
Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Type:
Grant
Filed:
April 27, 2022
Date of Patent:
November 22, 2022
Assignee:
Etubics Corporation
Inventors:
Joseph P. Balint, Frank R. Jones, Richard B. Gayle, III
Abstract: Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.
Abstract: Peptides related to certain portions of the arginine deiminase enzyme from the bacterium Streptococcus cristatus are provided that disrupt the formation and composition of biofilms containing the oral pathogen Porphyromonas gingivalis, and also modulate the virulence of P. gingivalis. Pharmaceutical compositions containing such peptides and method of using the same are disclosed.
Abstract: The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and/or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and/or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and/or prevention of cancer, sepsis and/or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.
Abstract: Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STa-toxoid-LTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.
Type:
Grant
Filed:
May 7, 2020
Date of Patent:
August 2, 2022
Assignees:
The Johns Hopkins University, South Dakota State University
Abstract: The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in Haemophilus influenzae, having an amino acid sequence as described in SEQ ID NO 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pE(A)) or truncated variants thereof based on said surface exposed protein. Nucleic acid sequences, vaccines, plasmids and phages, non human hosts, recombinant nucleic acid sequences, fusion proteins and fusion products are also described. A method of producing the said protein or truncated fragments thereof recombinantly is also disclosed.
Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
July 19, 2022
Assignee:
Etubics Corporation
Inventors:
Joseph P. Balint, Frank R. Jones, Richard B. Gayle, III
Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.
Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Type:
Grant
Filed:
September 14, 2016
Date of Patent:
July 5, 2022
Assignee:
Etubics Corporation
Inventors:
Joseph P. Balint, Frank R. Jones, Richard B. Gayle
Abstract: The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
June 28, 2022
Assignee:
The Board of Trustees of the University of Illinois
Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Type:
Grant
Filed:
September 14, 2016
Date of Patent:
June 28, 2022
Assignee:
Etubics Corporation
Inventors:
Joseph P. Balint, Frank R. Jones, Richard B. Gayle
Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Type:
Grant
Filed:
September 18, 2012
Date of Patent:
May 31, 2022
Assignee:
Etubics Corporation
Inventors:
Joseph P. Balint, Frank R. Jones, Richard B. Gayle, III
Abstract: Single-domain antibodies (SAbs) against three Yersinia pestis surface proteins (LcrV, YscF, and F1), nucleic acid sequences encoding the SAbs, and polypeptides comprising two or more SAbs capable of recognizing two or more epitopes and/or antigens. The present invention further includes methods for preventing or treating Y. pestis infections in a patient; methods for detecting and/or diagnosing Y. pestis infections; and devices and methods for identifying and/or detecting Y. pestis on a surface and/or in an environment.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
May 24, 2022
Assignee:
United States of America as represented by the Secretary of the Air Force
Inventors:
Camilla A Mauzy, Serge Victor Marie Muyldermans
Abstract: The present invention relates to an immunogenic fusion protein comprising a first amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, which is fused to a second amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a second group B Streptococcus surface protein. Each of the first and the second group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp1 protein, Alp2 protein, Alp3 protein, Alp4 protein and AlpC protein. The immunogenic fusion protein further comprises at least one amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of the group B streptococcus surface protein Alp1, Alp2, Alp3 or Alp4.
Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
Type:
Grant
Filed:
January 19, 2018
Date of Patent:
April 19, 2022
Assignees:
Brookhaven Science Associates, LLC, The Research Foundation of State University of New York, Baxalta Incorporated, Baxalta GmbH
Inventors:
Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft